Case Study: a leading biotech achieves smarter oncology portfolio prioritization with Evaluate Consulting

Leading Biotech screens 4,700 assets with Evaluate to prioritize oncology pipeline

The customer, a leading biotech, partnered with vendor Evaluate to address the challenge of identifying and prioritizing high-potential oncology assets for in-licensing. Their goal was to develop a bespoke, dynamic asset prioritization model aligned with their strategy to drive portfolio growth and future revenue generation.

Evaluate implemented a solution that involved screening over 4,700 assets using data from Evaluate Pharma. They built a custom, dynamic prioritization model to quantitatively compare assets and conducted tailored secondary research on the top candidates. The impact was that Evaluate enabled the biotech to confidently select five high-potential assets for further research and negotiation.